应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KRTX Karuna Therapeutics
停牌 03-28 14:33:17 EDT
329.83
+0.00
0.00%
最高
329.83
最低
329.83
成交量
0.00
今开
329.83
昨收
329.83
日振幅
0.00%
总市值
125.82亿
流通市值
119.62亿
总股本
3,815万
成交额
6.16亿
换手率
0.00%
流通股本
3,627万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
BUZZ-穆迪称因GLP-1药物推动制药业前景转为 "积极
Reuters · 03-14
BUZZ-穆迪称因GLP-1药物推动制药业前景转为 "积极
Karuna Therapeutics Inc盘中异动 早盘股价大跌5.26%报303.42美元
自选股智能写手 · 02-26
Karuna Therapeutics Inc盘中异动 早盘股价大跌5.26%报303.42美元
卡鲁纳治疗公司(Karuna Therapeutics Inc)公布截至 12 月的季度业绩 - 收益摘要
Reuters · 02-23
卡鲁纳治疗公司(Karuna Therapeutics Inc)公布截至 12 月的季度业绩 - 收益摘要
Karuna Therapeutics Inc 预计每股亏损 2.65 美元 - 财报前瞻
Reuters · 02-19
Karuna Therapeutics Inc 预计每股亏损 2.65 美元 - 财报前瞻
百时美施贵宝第四季度业绩好于预期
Reuters · 02-02
百时美施贵宝第四季度业绩好于预期
未来一天的看点 - 2月2日星期五
Reuters · 02-02
未来一天的看点 - 2月2日星期五
ETF追踪 | 生物科技行业2024:交易激增、创新迎来曙光
ETF小帮手 · 2023-12-31
ETF追踪 | 生物科技行业2024:交易激增、创新迎来曙光
Karuna Therapeutics Inc股价上涨47.36% 市值涨56.66亿美元
自选股智能写手 · 2023-12-22
Karuna Therapeutics Inc股价上涨47.36% 市值涨56.66亿美元
Karuna Therapeutics Inc盘中异动 下午盘急速拉升5.02%报213.93美元
自选股智能写手 · 2023-12-13
Karuna Therapeutics Inc盘中异动 下午盘急速拉升5.02%报213.93美元
分析师称,艾伯维斥资 87 亿美元押注 Cerevel 风险很大,但很明智
Reuters · 2023-12-08
分析师称,艾伯维斥资 87 亿美元押注 Cerevel 风险很大,但很明智
Karuna Therapeutics Inc跌4.63% 股价跌破200美元大关
自选股智能写手 · 2023-12-07
Karuna Therapeutics Inc跌4.63% 股价跌破200美元大关
Karuna Therapeutics Inc2023财年第三财季实现净利润-1.19亿美元,同比减少54.63%
自选股智能写手 · 2023-11-11
Karuna Therapeutics Inc2023财年第三财季实现净利润-1.19亿美元,同比减少54.63%
Karuna Therapeutics Inc盘中异动 临近收盘快速上涨5.08%
自选股智能写手 · 2023-10-05
Karuna Therapeutics Inc盘中异动 临近收盘快速上涨5.08%
加载更多
公司概况
公司名称:
Karuna Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Karuna Therapeutics, Inc.于2009年7月根据特拉华州法律注册成立。他们是一家创新的临床阶段生物制药公司,主要致力于开发新疗法,以解决以严重未满足的医疗需求为特征的致残神经精神病症。他们的产品系列建立在其主要候选药物KarXT的广泛治疗潜力之上,KarXT是一种毒蕈碱受体的口服调节剂,位于中枢神经系统或中枢神经系统以及各种外周组织中。KarXT是他们的专利候选产品,它将新型毒蕈碱激动剂xanomeline与经批准的毒蕈碱拮抗剂trospium结合,优先刺激中枢神经系统中的毒蕈碱受体。他们目前正在进行KarXT的2期临床试验,用于治疗精神分裂症患者的急性精神病,并期望在2019年末获得最终结果。
发行价格:
--
{"stockData":{"symbol":"KRTX","market":"US","secType":"STK","nameCN":"Karuna Therapeutics","latestPrice":329.83,"timestamp":1710532800000,"preClose":329.83,"halted":3,"volume":0,"delay":0,"floatShares":36267770,"shares":38147652,"eps":-11.734068,"marketStatus":"停牌","marketStatusCode":2,"change":0,"latestTime":"03-28 14:33:17 EDT","open":329.83,"high":329.83,"low":329.83,"amount":616303666.27764,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.734068,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1711656000000},"adr":0,"listingDate":1561694400000,"adjPreClose":329.83,"volumeRatio":0},"requestUrl":"/m/hq/s/KRTX","defaultTab":"news","newsList":[{"id":"2419983375","title":"BUZZ-穆迪称因GLP-1药物推动制药业前景转为 \"积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2419983375","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419983375?lang=zh_cn&edition=full","pubTime":"2024-03-14 22:35","pubTimestamp":1710426957,"startTime":"0","endTime":"0","summary":" 3月14日 - ** 穆迪评级公司称,GLP-1 和其他大片药物已将美国制药业信贷展望从 \"稳定 \"提升至 \"积极\"。** 评级机构表示,该行业的增长将受益于大片药物使用量的增加,包括诺和诺德 和礼来 的GLP-1糖尿病和减肥治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414839793","title":"Karuna Therapeutics Inc盘中异动 早盘股价大跌5.26%报303.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414839793","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414839793?lang=zh_cn&edition=full","pubTime":"2024-02-26 23:43","pubTimestamp":1708962236,"startTime":"0","endTime":"0","summary":"北京时间2024年02月26日23时43分,Karuna Therapeutics Inc股票出现异动,股价急速下跌5.26%。截至发稿,该股报303.42美元/股,成交量33.5563万股,换手率0.88%,振幅4.78%。Karuna Therapeutics Inc股票所在的生物技术行业中,整体跌幅为0.08%。Karuna Therapeutics Inc公司简介:Karuna Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发新疗法,以解决因未满足的医疗需求而导致的神经精神疾病致残问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402262343567914b601&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402262343567914b601&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413201419","title":"卡鲁纳治疗公司(Karuna Therapeutics Inc)公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2413201419","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413201419?lang=zh_cn&edition=full","pubTime":"2024-02-23 11:02","pubTimestamp":1708657331,"startTime":"0","endTime":"0","summary":" * Karuna Therapeutics Inc 报告了截至12月底的季度调整后每股亏损3.01美元,低于去年同期的每股亏损2.22美元。二十位分析师对该季度的平均预期是每股亏损 2.65 美元。华尔街预期为每股亏损 3.79 美元至 2.12 美元。* Karuna Therapeutics Inc 报告的本季度每股收益为亏损 3.01 美元。* 该公司一季度亏损 1.1382 亿美元。* Karuna Therapeutics Inc 的股价本季度上涨了 0.8%。华尔街对 Karuna Therapeutics Inc 的 12 个月目标价中位数为 330.00 美元。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412139629","title":"Karuna Therapeutics Inc 预计每股亏损 2.65 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2412139629","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412139629?lang=zh_cn&edition=full","pubTime":"2024-02-19 22:23","pubTimestamp":1708352596,"startTime":"0","endTime":"0","summary":" * Karuna Therapeutics Inc 预计将在2月21日公布截至2023年12月31日的业绩() 时显示季度收入下降。* 根据 LSEG 数据,17 位分析师的平均预期显示,这家总部位于波士顿马萨诸塞州的公司的营收预计将从去年同期的 528 万美元下降 85.6%,至 76118 万美元。 * LSEG 的分析师平均预计 Karuna Therapeutics Inc 每股亏损 2.65 美元。* 华尔街对 Karuna Therapeutics Inc 的 12 个月目标价中位数为 330.00 美元,高于其最新收盘价 318.25 美元。2月19日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408044186","title":"百时美施贵宝第四季度业绩好于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2408044186","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408044186?lang=zh_cn&edition=full","pubTime":"2024-02-02 19:59","pubTimestamp":1706875153,"startTime":"0","endTime":"0","summary":" Michael Erman 路透2月2日 - 制药商百时美施贵宝 周五公布的第四季度业绩好于预期,原因是其贫血症新药Reblozyl和已退出专利的血癌药物Revlimid的销售业绩超过了华尔街的预测。该公司去年底宣布了一系列交易,以重新储备其产品线,并表示其第四季度收入为 114.8 亿美元。百时美施贵宝预计,随着癌症免疫疗法Opdivo和血液稀释剂Eliquis失去专利保护,这两种畅销药物在本十年晚些时候的销售额将有所下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408061665","title":"未来一天的看点 - 2月2日星期五","url":"https://stock-news.laohu8.com/highlight/detail?id=2408061665","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408061665?lang=zh_cn&edition=full","pubTime":"2024-02-02 03:45","pubTimestamp":1706816727,"startTime":"0","endTime":"0","summary":"根据 LSEG 的估计,受能源价格影响,全年净利润预计为 374 亿美元,低于 2022 年的 591 亿美元。预计 1 月份非农就业岗位将增加 180,000 个,12 月份为 216,000 个。1 月份的失业率可能从 12 月份的 3.7% 上升至 3.8%。同时,1 月份平均时薪预计将增长 0.3%,12 月份为增长 0.4%。工资同比增幅可能为 4.1%,与上月持平。另外,美国商务部人口普查局的数据预计将显示,12 月份工厂订单增长 0.2%,而 11 月份为增长 2.6%。医疗保险公司 Cigna Group 预计将公布第四季度财报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"1185510638","title":"ETF追踪 | 生物科技行业2024:交易激增、创新迎来曙光","url":"https://stock-news.laohu8.com/highlight/detail?id=1185510638","media":"ETF小帮手","top":-1,"share":"https://www.laohu8.com/m/news/1185510638?lang=zh_cn&edition=full","pubTime":"2023-12-31 20:11","pubTimestamp":1704024683,"startTime":"0","endTime":"0","summary":"生物科技行业正在迎来复苏,摆脱了一段时间的低迷。展望2024年,分析师们预计更有利的利率环境、交易活动的增加,以及在癌症和免疫学等关键领域的创新将为生物技术公司带来更为光明的前景。自10月底以来,生物科技行业的指数已经上涨了29%。这两个行业在截至2023年12月28日的12个月内共进行了超2220亿美元的并购交易。该 ETF 目前拥有约 275 只生物科技股票。ETF 通常持有 40 至 60 只股票。方舟基因革命ETF于2014年开始交易。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2393142490","title":"Karuna Therapeutics Inc股价上涨47.36% 市值涨56.66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2393142490","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2393142490?lang=zh_cn&edition=full","pubTime":"2023-12-22 22:32","pubTimestamp":1703255532,"startTime":"0","endTime":"0","summary":"北京时间2023年12月22日22时32分,Karuna Therapeutics Inc股票出现异动,股价快速拉升47.36%。Karuna Therapeutics Inc股票所在的生物技术行业中,整体涨幅为1.16%。消息层面,截至22时32分,《Karuna盘前大涨46% 获施贵宝140亿美元收购》资讯为影响Karuna Therapeutics Inc的重要信息。美股盘前,Karuna 股价上涨了46%,而百时美施贵宝的股价下跌了1.9%。百时美施贵宝还在10月份宣布以48亿美元收购Mirati Therapeutics,以扩大其抗癌药物产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231222223212816e73bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231222223212816e73bc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2391085813","title":"Karuna Therapeutics Inc盘中异动 下午盘急速拉升5.02%报213.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2391085813","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2391085813?lang=zh_cn&edition=full","pubTime":"2023-12-13 03:19","pubTimestamp":1702408785,"startTime":"0","endTime":"0","summary":"北京时间2023年12月13日03时19分,Karuna Therapeutics Inc股票出现异动,股价大幅拉升5.02%。截至发稿,该股报213.93美元/股,成交量13.8578万股,换手率0.37%,振幅5.50%。Karuna Therapeutics Inc股票所在的生物技术行业中,整体涨幅为1.02%。Karuna Therapeutics Inc公司简介:Karuna Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发新疗法,以解决因未满足的医疗需求而导致的神经精神疾病致残问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121303194579011f24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121303194579011f24&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2389107617","title":"分析师称,艾伯维斥资 87 亿美元押注 Cerevel 风险很大,但很明智","url":"https://stock-news.laohu8.com/highlight/detail?id=2389107617","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389107617?lang=zh_cn&edition=full","pubTime":"2023-12-08 02:30","pubTimestamp":1701973829,"startTime":"0","endTime":"0","summary":"总部位于伊利诺伊州北芝加哥的艾伯维公司周三晚些时候说 ,它将以 87 亿美元的价格收购 Cerevel,从而获得一系列正在测试的治疗神经系统疾病的药物组合,其中包括治疗精神分裂症的 emraclidine。分析师说,Cerevel 公司仍在进行 emraclidine 的中期试验,这意味着这笔交易并没有 \"去风险\",因为该疗法可能会在试验中失败。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2389902117","title":"Karuna Therapeutics Inc跌4.63% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2389902117","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2389902117?lang=zh_cn&edition=full","pubTime":"2023-12-07 22:34","pubTimestamp":1701959657,"startTime":"0","endTime":"0","summary":"北京时间2023年12月07日22时34分,Karuna Therapeutics Inc股票出现异动,股价急速跳水4.63%。Karuna Therapeutics Inc股票所在的生物技术行业中,整体涨幅为0.07%。Karuna Therapeutics Inc公司简介:Karuna Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发新疗法,以解决因未满足的医疗需求而导致的神经精神疾病致残问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231207223417806b212d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231207223417806b212d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2382370917","title":"Karuna Therapeutics Inc2023财年第三财季实现净利润-1.19亿美元,同比减少54.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2382370917","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2382370917?lang=zh_cn&edition=full","pubTime":"2023-11-11 00:22","pubTimestamp":1699633332,"startTime":"0","endTime":"0","summary":"9月30日,Karuna Therapeutics Inc公布财报,公告显示公司2023财年第三财季净利润为-1.19亿美元,同比减少54.63%;其中营业收入为0.00美元,每股基本收益为-3.16美元。机构评级:截至2023年9月30日,当前有19家机构对Karuna Therapeutics Inc目标价做出预测,其中目标均价为265.95美元,其中最低目标价为197.00美元,最高目标价为320.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202311110022148264f7a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202311110022148264f7a0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2373807968","title":"Karuna Therapeutics Inc盘中异动 临近收盘快速上涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2373807968","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2373807968?lang=zh_cn&edition=full","pubTime":"2023-10-05 03:58","pubTimestamp":1696449523,"startTime":"0","endTime":"0","summary":"北京时间2023年10月05日03时58分,Karuna Therapeutics Inc股票出现异动,股价急速拉升5.08%。Karuna Therapeutics Inc股票所在的生物技术行业中,整体涨幅为0.99%。Karuna Therapeutics Inc公司简介:Karuna Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发新疗法,以解决因未满足的医疗需求而导致的神经精神疾病致残问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310050358448390a046&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310050358448390a046&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.karunatx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0438},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.9506},{"period":"1year","weight":0.8319},{"period":"ytd","weight":0.0421}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0975},{"period":"6month","weight":0.2238},{"period":"1year","weight":0.3225},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Karuna Therapeutics, Inc.于2009年7月根据特拉华州法律注册成立。他们是一家创新的临床阶段生物制药公司,主要致力于开发新疗法,以解决以严重未满足的医疗需求为特征的致残神经精神病症。他们的产品系列建立在其主要候选药物KarXT的广泛治疗潜力之上,KarXT是一种毒蕈碱受体的口服调节剂,位于中枢神经系统或中枢神经系统以及各种外周组织中。KarXT是他们的专利候选产品,它将新型毒蕈碱激动剂xanomeline与经批准的毒蕈碱拮抗剂trospium结合,优先刺激中枢神经系统中的毒蕈碱受体。他们目前正在进行KarXT的2期临床试验,用于治疗精神分裂症患者的急性精神病,并期望在2019年末获得最终结果。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.017851},{"month":2,"riseRate":0.6,"avgChangeRate":0.025207},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008771},{"month":4,"riseRate":0.5,"avgChangeRate":0.012196},{"month":5,"riseRate":0.75,"avgChangeRate":0.053662},{"month":6,"riseRate":0.75,"avgChangeRate":0.094204},{"month":7,"riseRate":0.4,"avgChangeRate":-0.079541},{"month":8,"riseRate":0.6,"avgChangeRate":0.190327},{"month":9,"riseRate":0.4,"avgChangeRate":-0.070236},{"month":10,"riseRate":0.4,"avgChangeRate":0.002205},{"month":11,"riseRate":0.8,"avgChangeRate":0.904839},{"month":12,"riseRate":0.8,"avgChangeRate":0.116197}],"exchange":"NASDAQ","name":"Karuna Therapeutics","nameEN":"Karuna Therapeutics"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Karuna Therapeutics(KRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Karuna Therapeutics(KRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Karuna Therapeutics,KRTX,Karuna Therapeutics股票,Karuna Therapeutics股票老虎,Karuna Therapeutics股票老虎国际,Karuna Therapeutics行情,Karuna Therapeutics股票行情,Karuna Therapeutics股价,Karuna Therapeutics股市,Karuna Therapeutics股票价格,Karuna Therapeutics股票交易,Karuna Therapeutics股票购买,Karuna Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Karuna Therapeutics(KRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Karuna Therapeutics(KRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}